Tumor microenvironment (TME) includes a wide variety of cell types and soluble factors
capable of suppressing immune-responses. While the role of NK cells in TME has been …

Lung cancer is one of the common malignant cancers worldwide. Immune checkpoint
inhibitor (ICI) therapy has improved survival of lung cancer patients. However, ICI therapy …

Background The tumor immune microenvironment (TIME) phenotypes have been reported
to mainly impact the efficacy of immunotherapy. Given the increasing use of immunotherapy …

Abstract Programmed death-ligand 1 (PD-L1) expression is currently used in the clinic to
assess eligibility for immune-checkpoint inhibitors via the tumor proportion score (TPS), but …

Immunotherapy can improve the survival of patients with advanced lung squamous cell
carcinoma (LUSC). T cytotoxic cells are one of the main members of the immune …

Background Previous studies have suggested that patients with pulmonary sarcomatoid
carcinoma (PSC) may benefit from immune checkpoint inhibitors (ICIs); however, relevant …

Purpose: Our understanding of the immunopathology of resectable non–small cell lung
cancer (NSCLC) is still limited. Here, we explore immune programs that inform of tumor …

Monoclonal antibodies that target specific ligand-receptor signaling pathways and act as
immune checkpoint inhibitors have been designed to remove the brakes in T cells and …

Background High immune infiltration is associated with favourable prognosis in patients with
non-small-cell lung cancer (NSCLC), but an automated workflow for characterizing immune …

Immunotherapy is a promising strategy for triple-negative breast cancer (TNBC) patients,
however, the overall survival (OS) of 5-years is still not satisfactory. Hence, developing more …